000999SZSE

Huatai United Securities' Special Continuous Supervision Opinion on China Resources Sanjiu's Major Asset Acquisition in 2025

China Resources Sanjiu Medical and Pharmaceutical Co., Ltd.·

✨ AI Summary

Huatai United Securities issued a special continuous supervision opinion regarding China Resources Sanjiu's acquisition of a controlling stake in Kunming Pharmaceutical Group, involving 208,976,160 shares (27.56% of total shares). The transaction was approved by the board and shareholders in 2022, with a commitment to resolve competition issues within five years. As of April 2026, measures have been taken to address competition regarding Xuesaitong Soft Capsules, while other commitments remain under resolution.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· OpenAI

Huatai United Securities Co., Ltd. Regarding China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Special Continuous Supervision Opinion on Major Asset Purchase for 2025 Independent Financial Advisor Date of Signing: April 2026 1

Independent Financial Advisor Statement

Huatai United Securities Co., Ltd. (hereinafter referred to as "Huatai United Securities" or "Independent Financial Advisor") serves as the independent financial advisor for the major asset purchase of control over Kunming Pharmaceutical Group Co., Ltd. (hereinafter referred to as "this transaction") by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

In accordance with the relevant requirements of the Company Law, Securities Law, Measures for the Administration of Major Asset Restructuring, and Measures for the Management of Financial Advisory Business for Mergers and Acquisitions of Listed Companies, this independent financial advisor has conducted prudent verification and, in conjunction with the 2025 annual report of the listed company, issues this special continuous supervision opinion on the major asset restructuring.

The following statements are made:

  1. The documents and materials on which this special continuous supervision opinion is based were provided by the parties to the transaction. All parties to this transaction have assured this independent financial advisor that the relevant information provided regarding this major asset restructuring is true, accurate, and complete, with no false records, misleading statements, or material omissions.
  2. This independent financial advisor has fulfilled its due diligence obligations as required and has sufficient reason to believe that the professional opinions expressed do not have substantial differences from the contents disclosed by the listed company.
  3. This special continuous supervision opinion does not constitute any investment advice for the listed company. The independent financial advisor does not bear any responsibility for any risks arising from investment decisions made by investors based on this special continuous supervision opinion.
  4. This independent financial advisor has not entrusted or authorized any other institutions or individuals to provide information not included in this special continuous supervision opinion or to make any interpretations or explanations regarding this special continuous supervision opinion.
  5. This independent financial advisor urges investors to carefully read the full text of the documents related to this transaction published by the listed company. 2

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Sign in to read moreSee Pro pricing